Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06596291 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization
A Phase 1 study of Spinal Cord Injuries and Neurogenic Detrusor Overactivity, sponsored by EG 427.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 4
- Study locations
NCT06596291: Recruiting Phase 1 study of Spinal Cord Injuries and Neurogenic Detrusor Overactivity, sponsored by EG 427.
NCT06596291 is a Phase 1 study of Spinal Cord Injuries and Neurogenic Detrusor Overactivity that is actively recruiting participants, run by EG 427. The registered enrollment target is 16 participants, below the 62-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (74% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06596291, a Phase 1 study of Spinal Cord Injuries and Neurogenic Detrusor Overactivity, is actively recruiting participants, sponsored by EG 427.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a first-in-human, Phase 1b/2a, open-label, dose-escalation study of a single treatment course consisting of multiple intradetrusor injections of EG110A in male and female adult participants with Neurogenic Detrusor Overactivity (NDO)-related incontinence following Spinal Cord Injury (SCI), who have persistent incontinence after standard of care therapy and who perform Clear Intermittent Catheterization (CIC) on a regular basis.
Primary Outcome
Any participant who has a reported treatment-emergent adverse events (TEAEs)
Conditions Studied
Interventions
- DRUG EG110A
Study Locations (4)
California
- Rancho Los Amigos National Rehabilitation Center - Downey
Michigan
- University of Michigan Rogel Cancer Center - Ann Arbor
Pennsylvania
- Sidney Kimmel Medical College - Philadelphia
Texas
- UTHealth Houston / TIRR Memorial Hermann - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2025-01-08 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
What NCT06596291 shows while recruiting
NCT06596291 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 62-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (74% lower).
The record links to 2 conditions, with Spinal Cord Injuries appearing as the primary indexed condition, and to 1 intervention - of which EG110A is the first listed.
NCT06596291 reports a single indexed study location in California, Michigan, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06596291 about?
NCT06596291 is a clinical study titled "Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization". This is a first-in-human, Phase 1b/2a, open-label, dose-escalation study of a single treatment course consisting of multiple intradetrusor injections of EG110A in male and female adult participants with Neurogenic Detrusor Overactivity (NDO)-related incontinence following Spinal Cord Injury (SCI), w...
What is the current status of trial NCT06596291?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2025-01-08. Estimated completion is 2027-06.
What conditions does trial NCT06596291 study?
This clinical trial studies the following conditions: Spinal Cord Injuries, Neurogenic Detrusor Overactivity.
What interventions are being tested in trial NCT06596291?
The interventions under investigation include: EG110A (DRUG).
Who is sponsoring clinical trial NCT06596291?
This trial is sponsored by EG 427, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06596291 being conducted?
This trial has 4 study locations across California, Michigan, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spinal Cord Injuries
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06596291's enrollment target sits among peer trials
16 145th of 202 higher than 53 of 202 other Spinal Cord Injuries trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Spinal Cord Injuries trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Bacteriophage Therapy in Spinal Cord Injury Patients With Bacteriuria
RECRUITING · Phase 1
-
NVG-291 in Spinal Cord Injury Subjects
RECRUITING · Phase 1
-
Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury
RECRUITING · Phase 1
-
Temporary Inactivation of Strong Muscle Sensation to Improve Rehabilitation Interventions in SCI
ACTIVE NOT RECRUITING · Phase 1
-
Pharmacological Agents for Chronic Spinal Cord Injury (SCI)
COMPLETED · Phase 1
-
Improving Functioning in Persons With Chronic Pain Post-SCI Through Virtual Classroom Education
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy